Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models

The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special interest in neurolog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS chemical neuroscience 2015-04, Vol.6 (4), p.666-680
Hauptverfasser: Roy, Saktimayee M, Grum-Tokars, Valerie L, Schavocky, James P, Saeed, Faisal, Staniszewski, Agnieszka, Teich, Andrew F, Arancio, Ottavio, Bachstetter, Adam D, Webster, Scott J, Van Eldik, Linda J, Minasov, George, Anderson, Wayne F, Pelletier, Jeffrey C, Watterson, D. Martin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!